10-K: RxSight Reports 2023 Financial Results, Highlights Growth in Light Adjustable Lens Adoption

RxSight, Inc. reports a significant increase in revenue and installed base for its Light Adjustable Lens system in its 2023 annual filing.

Summary

• RxSight, Inc. is a medical technology company focused on improving vision after cataract surgery using its Light Adjustable Lens (LAL) system.
• The RxSight system includes the LAL, a Light Delivery Device (LDD), and related accessories.
• The LAL is a premium intraocular lens that can be adjusted post-surgery using UV light from the LDD.
• The company's 2023 premium procedures represented about 21% of all cataract procedures in the United States, generating approximately $780 million in revenue.
• The premium IOL market is projected to grow at a 9.5% compound annual growth rate (CAGR) by 2028.
• In a clinical trial, 70% of LAL patients achieved 20/20 or better uncorrected visual acuity, compared to about 40% in similar trials of other premium IOLs.
• As of December 31, 2023, RxSight had an installed base of 666 LDDs and surgeons have implanted over 96,000 LALs since inception.
• The company's commercial efforts are primarily focused in the United States, targeting approximately 4,000 cataract surgeons.
• The company's research and development activities are focused on improving clinical outcomes, customer experience, expanding indications, and reducing manufacturing costs.
• The company's manufacturing capacity is sufficient to meet current expected demand for at least the next 12 months.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and successful clinical outcomes. However, the company's history of losses and reliance on third parties introduce some risk, resulting in a high but not perfect sentiment score.

Positives

• The RxSight system allows for full customization and optimization of patient vision after surgery.
• The LAL delivers superior visual outcomes with a low risk of side effects.
• The system provides accuracy and precision to optimize vision with both eyes.
• Patients can preview and compare possible vision outcomes before selecting a final prescription.
• The RxSight system empowers doctors to grow their practices with a premium IOL they can trust.
• The company has a vertically integrated manufacturing strategy, offering control over product quality and rapid product iteration.
• The company has received ISO 13485:2016 certification for its quality management system.
• The company has received quality system certification to the Medical Device Single Audit Program (MDSAP).
• The company has a dual aspect payment model in the United States, making it eligible for reimbursement.
• The company has a strong intellectual property portfolio covering various aspects of its LDD, LAL, and related devices and methods.

Negatives

• The company has a history of net operating losses and expects to continue to incur losses in the future.
• The company faces significant competition from larger, well-established companies.
• The company depends on third parties, including single and sole source suppliers, for certain components and subcomponents.
• The company's stock price may be volatile.
• The company's products require patients to wear UV protective glasses for 4-5 weeks after surgery and require additional clinic visits compared to traditional cataract surgery.
• The company's products are subject to extensive and ongoing regulation by the FDA and other regulatory authorities.
• The company's ability to use net operating loss carryforwards may be subject to certain limitations.
• The company's facilities are located in an area prone to earthquakes and fires.

Risks

• The company has a limited operating history and may fail to effectively train its sales force or develop broad brand awareness.
• The company may not be able to sustain profitability even if achieved.
• The company's success depends on the RxSight system, and failure to market it successfully will harm the business.
• The company faces significant competition and may not be able to achieve or maintain market penetration.
• Global economic and political conditions may adversely affect the company's business.
• The company's cash, cash equivalents, and short-term investments could be adversely affected if the financial institution holding them fails.
• The company may be unable to obtain, maintain, protect, and enforce intellectual property rights.
• The company may be unable to protect the confidentiality of trade secrets.
• The company may fail to obtain and maintain necessary regulatory clearances or approvals.
• The company depends on third parties for manufacturing components, making it vulnerable to supply disruptions.
• The company's stock price may be volatile, and an active trading market may not exist.
• The company is highly dependent on its management team.
• Future litigation proceedings could adversely affect the company.
• The company may experience a significant disruption in its information technology systems or breaches of data security.
• The company may expend limited resources on a particular product or indication and fail to capitalize on more profitable opportunities.
• The company may not be able to develop, license, or acquire new products or enhance existing products.
• The company may not be able to achieve or maintain satisfactory pricing and margins.
• The company's quarterly and annual results may fluctuate significantly.
• The company may encounter difficulties in managing its growth.
• The company may be subject to product liability lawsuits.
• The company may experience difficulties in obtaining regulatory clearance or successfully marketing products internationally.
• The company may not be able to achieve or maintain satisfactory pricing and margins for its products.
• The sizes of the markets for the company's products may be smaller than estimated.
• Changes in state regulations and interpretation of the practice of optometry may affect the adoption of the company's products.
• The company may not be able to achieve or maintain satisfactory pricing and margins for its products.
• The company may be unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers.

Future Outlook

The company plans to grow its business by expanding its LDD installed base and driving increased utilization of its LAL through heightened awareness of the superior clinical outcomes its RxSight system provides patients. The company also plans to continue to invest in research and development to improve its products and expand its indications.

Management Comments

• The company believes its RxSight system provides doctors and patients increased confidence and peace of mind by eliminating the high-stakes preoperative guesswork common to competitive premium IOLs and allowing patients to iterate their final vision characteristics with customized post-surgical adjustments.
• The company believes that the premium cataract surgery market remains underpenetrated due to both doctors reluctance to recommend competitive premium IOLs to the full universe of eligible patients and patients confusion in assessing the associated trade-offs and side effects with competitive premium IOLs.
• The company believes its RxSight system offers doctors and patients a significantly more reliable approach that can consistently deliver optimal, fully customized visual outcomes with few compromises, ultimately driving broad adoption and establishing it as the standard of care for premium cataract procedures.

Industry Context

The announcement highlights RxSight's position in the growing premium IOL market, which is projected to grow at a 9.5% CAGR by 2028. The company's technology addresses the limitations of existing premium IOLs by offering post-operative adjustability, which is a key differentiator in the market.

Comparison to Industry Standards

• The company's clinical trial results show that 70% of LAL patients achieved 20/20 or better uncorrected visual acuity, which is significantly higher than the 38.4% and 43.6% reported by Alcon's Acrysof Toric and J&J's Tecnis Toric IOLs, respectively, in their pivotal studies.
• The company's most recent Phase IV commercial study data shows that over 90% of LAL patients achieved 20/20 distance vision and were able to read 5-point font without glasses, which is approximately twice the rate of any of the alternative IOLs.
• The company's LALs do not induce higher rates of glare and halos compared to monofocal IOLs, unlike multifocal IOLs, which are associated with a higher incidence of unwanted side effects.
• The company's LALs can reduce the potential for secondary surgical procedures by correcting residual refractive error after surgery, unlike other premium IOLs, which often require a separate LASIK procedure.

Corporate Governance

Legal Proceedings

• The company may become involved in litigation or other legal proceedings from time to time.
• The company is not currently a party to any litigation or legal proceedings that are likely to have a material adverse effect on its business.

Stakeholder Impact

• Shareholders may benefit from the company's growth and potential for future profitability.
• Employees may benefit from the company's growth and potential for future success.
• Customers (doctors and patients) may benefit from the company's innovative technology and improved visual outcomes.
• Suppliers may benefit from the company's increased demand for components and subcomponents.
• Creditors may benefit from the company's improved financial performance and ability to repay debt.

Next Steps

• The company plans to expand its LDD installed base.
• The company plans to drive increased utilization of its LAL.
• The company plans to continue to invest in research and development.
• The company may selectively pursue commercial expansion outside the United States.
• The company may seek new approvals in large cataract markets with more complex regulatory environments such as Asia.

Key Dates

Keywords

Light Adjustable Lens, Cataract Surgery, Intraocular Lens, Premium IOL, RxSight, Light Delivery Device, Visual Acuity, Ophthalmology, Medical Device, FDA Approval